Lipocine Debt-to-Equity Ratio Growth & History (LPCN)

Lipocine's debt-to-equity ratio was 0.04 for fiscal 2021.

View full Lipocine company overview

Lipocine annual debt-to-equity ratio history

Lipocine annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20212021-12-310.04−0.33−89.96%
20202020-12-310.36−0.77−67.95%
20192019-12-311.140.05+4.52%
20182018-12-311.091.09
20172017-12-310.00

Lipocine debt-to-equity ratio trends

Between the periods ended 2017-12-31 and 2021-12-31, Lipocine's debt-to-equity ratio increased from 0.00 to 0.04, a change of 0.04. The latest reported quarter, Q1 2022, shows 0.02.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Lipocine source filings ↗

Community posts

It’s quiet here.

No posts about LPCN yet. Start the conversation.

Write the first post